Dr. Drachman is Chief Executive Officer at Neoleukin Therapeutics. Previously, Dr. Drachman has served in a number of roles at Seattle Genetics, including Chief Medical Officer and Executive Vice President of Research and Development, where he played a key role in clinical development and advancing the pipeline of antibody-drug conjugates and immuno-oncology drug candidates. Dr. Drachman also served as a faculty member in the Hematology Division, Department of Medicine at the University of Washington in Seattle, and as a Senior Investigator in the Division of Research and Education at the Puget Sound Blood Center. Dr. Drachman received a B.A. in Biochemistry from Harvard University and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine and fellowship in Medical Oncology at the University of Washington.